• 5X Protein Loading Buffer (Reducing) Guide

  2026-08-12

  5X Protein Loading Buffer (Reducing) is a concentrated protein loading buffer for reducing SDS-PAGE sample preparation, where SDS denaturation and disulfide-bond reduction support protein molecular weight separation. It should be used for conventional denaturing electrophoresis and avoided when native protein conformation, intact disulfide-linked assemblies, or non-reducing conditions must be preserved.

• Gut Dysbiosis, STAT3, and Docetaxel Resistance

  2026-08-12

  Zhong et al. connect antibiotic-associated gut dysbiosis with prostate cancer progression and docetaxel resistance through a gut permeability–lipopolysaccharide–NF-κB-IL6-STAT3 pathway. By combining mouse tumor models, fecal microbiota transplantation, 16S rRNA sequencing, mechanistic assays, and patient samples, the study links microbial composition with both tumor biology and metastatic risk.

• AI Analysis of Urine Stem Cell Mitochondria in AD

  2026-08-11

  A 2025 Neurotherapeutics study developed a deep-learning workflow that classifies mitochondrial hyperfission and hyperfusion from live-cell fluorescence images of urine-derived stem cells. By connecting non-invasive cell collection with mitochondrial morphology analysis, the work provides a promising but preliminary route toward accessible Alzheimer’s disease and mild cognitive impairment biomarker research.

• Tankyrase Inhibitors and Hippo Signaling in HCC

  2026-08-11

  Jia et al. showed that the tankyrase inhibitors XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth while reducing YAP activity and increasing the YAP-negative regulators AMOTL1 and AMOTL2. The study connects tankyrase activity to Hippo pathway regulation and provides a mechanistic framework for evaluating tankyrase inhibition beyond its established links to Wnt signaling.

• Dacomitinib (PF-00299804) Cancer Research Workflows

  2026-08-10

  Dacomitinib (PF-00299804) provides a durable pan-HER perturbation strategy for mapping EGFR, HER2, and HER4 signaling, resistance, apoptosis, and cell-cycle responses. This applied guide connects receptor-level experiments with the mitochondrial ferroptosis framework reported in colorectal cancer while clearly separating validated evidence from exploratory assay design.

• Stattic for Reproducible STAT3 Assays

  2026-08-09

  A scenario-based guide to using Stattic as a mechanistic STAT3 inhibitor in viability, proliferation, apoptosis, and radiosensitization workflows. It explains how SKU A2224 supports better assay interpretation through defined potency, handling requirements, and pathway-focused controls.

• Nigericin sodium salt: Practical Assay Guide

  2026-08-08

  Nigericin sodium salt is a potassium ionophore for experimentally perturbing K+/H+ exchange, membrane ion gradients, and cytoplasmic pH in research assays. It is intended for controlled in vitro workflows, not diagnostic or therapeutic use, and its solvent limitations and ionic-environment dependence must be addressed during assay development.

• Seeing the Invisible in Translational Neuroscience

  2026-08-07

  Translational neuroscience increasingly depends on proving not only that an intervention works, but also where its molecular machinery is expressed. This thought-leadership article connects the K+-selective channelrhodopsin strategy reported by Duan and colleagues with the Fluorescein TSA Fluorescence System Kit, showing how high-sensitivity spatial assays can strengthen mechanistic validation without overstating preclinical evidence.

• Vasopressin Analogues: Multitasking Peptides in Therapy and

  2026-08-07

  The reference study systematically examines vasopressin and its analogues, highlighting the evolution from natural hormones to versatile therapeutic peptides. It provides a detailed account of molecular modifications, clinical applications, and emerging antiviral prospects, with lypressin acetate serving as a key example of translational peptide utility.

• ARCA EGFP mRNA (5-moUTP): Elevating Polyadenylated mRNA Assa

  2026-08-06

  ARCA EGFP mRNA (5-moUTP) sets a new benchmark for fluorescence-based transfection controls in mammalian cells, combining advanced cap analog and 5-methoxyuridine modifications to maximize stability, suppress innate immunity, and ensure robust, reproducible EGFP expression. This guide details optimized workflows, comparative advantages, and expert troubleshooting for researchers aiming for the highest standard in polyadenylated mRNA delivery and assay reliability.

• Structure-Guided Proteomimetics Inhibit SARS-CoV-2 S-RBD/hAC

  2026-08-06

  This study introduces a structure-guided approach for developing constrained proteomimetic inhibitors that disrupt the challenging SARS-CoV-2 Spike RBD/hACE2 protein–protein interaction. The findings advance strategies for targeting class III PPIs, with implications for both antiviral research and the broader design of next-generation PPI inhibitors.

• Homoharringtonine: Rapid SARS-CoV-2 Clearance in Preclinical

  2026-08-05

  A recent multi-institutional study demonstrates that homoharringtonine, a cytotoxic alkaloid, can rapidly clear SARS-CoV-2 from the upper respiratory tract in both animal models and clinical settings. These findings position homoharringtonine as a promising first-line antiviral candidate for future coronavirus outbreaks, with practical implications for translational research.

• Stattic-Enabled STAT3 Inhibition: New Horizons in HNSCC Rese

  2026-08-05

  This thought-leadership article explores the mechanistic underpinnings and translational impact of STAT3 inhibition using Stattic in head and neck squamous cell carcinoma (HNSCC) research. By integrating recent advances in STAT3-driven lymphangiogenesis, apoptosis, and radiosensitization, it provides actionable guidance for translational scientists, highlights experimental nuances, and frames the broader implications for cancer biology.

• Doxycycline: Applied Workflows for AAA & Cancer Research

  2026-08-04

  Doxycycline’s dual role as a tetracycline antibiotic and a broad-spectrum metalloproteinase inhibitor is transforming both vascular and cancer research models. This article translates recent nanomedicine advances and hands-on troubleshooting strategies into actionable protocols for maximizing reproducibility and translational value.

• Low-Molecular Weight Inhibitors Targeting Alternative Comple

  2026-08-04

  The reference study provides a comprehensive overview of the development and mechanistic understanding of low-molecular weight inhibitors targeting the alternative complement pathway, focusing on the therapeutic potential of factor B and factor D inhibitors. Its findings have significant implications for advancing complement-mediated disease research and developing targeted interventions.

11409 records 1/761 page Next 12345 下5页 Last page